Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 119 followers
Latest posts
Last updated about 18 hours ago
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
about 18 hours ago
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines...
Lilly Responds to American Hospital Association Letter to HRSA About 340B Program Changes
1 day ago
To prevent fraud, waste, and abuse in the 340B program, Lilly has...
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
10 days ago
INDIANAPOLIS , Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
11 days ago
INDIANAPOLIS , Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE...
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI
19 days ago
News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of...
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
23 days ago
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50%...
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
24 days ago
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies...
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
about 1 month ago
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for...
Lilly to participate in J.P. Morgan Healthcare Conference
about 2 months ago
INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
about 2 months ago
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus...
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
about 2 months ago
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg...
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
about 2 months ago
Huntsville site will focus on domestic production of small molecule synthetic and...